Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421].

Curr Control Trials Cardiovasc Med · 2001 · PMC57751 · PMID 11806795

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantP < 0.0001actually significant

All of these effects were highly significant ( P < 0.0001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.